Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
ISELIN, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference being held in New York, NY on Tuesday, September 26, 2023 at 1:35 PM ET.
In addition to the panel presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A live video webcast ofthe panel presentation will be accessible on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). A webcast replay will be archived for 90 days following the event.
About Outlook Therapeutics, Inc.
Continental Breakfast Served
Keynote Presentation by Avaya
UCaaS and MSPs: Driving Collaboration, Productivity, and Customer Experience